Amgen Inc.

Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics. The company's major products are Prolia and XGEVA (denosumab) to treat osteoporosis and bone diseases ($6.6 billion in total 2025 revenues), Repatha (evolocumab) to treat hyperlipidemia ($3.0 billion in 2025 revenues), Otezla (apremilast) to treat psoriasis and psoriatic arthritis ($2.3 billion in 2025 revenues), Enbrel (etanercept) to treat autoimmune diseases ($2.2 billion in 2025 revenues), Evenity (romosozumab) to treat osteoporosis ($2.1 billion in 2025 revenues), Tepezza (teprotumumab) to treat Graves' ophthalmopathy ($1.9 billion in 2025 revenues), Blincyto (blinatumomab) to treat acute lymphoblastic leukemia ($1.6 billion in 2025 revenues), Nplate (romiplostim) to regulate platelet production ($1.5 billion in 2025 revenues), Tezspire (tezepelumab) to treat asthma ($1.5 billion in 2025 revenues), Kyprolis (carfilzomib) to treat cancer ($1.4 billion in 2025 revenues), Aranesp (darbepoetin alfa) to stimulate erythropoiesis ($1.4 billion in 2025 revenues), Krystexxa (pegloticase) to treat gout ($1.3 billion in 2025 revenues), and Vectibix (panitumumab), a monoclonal antibody ($1.2 billion in 2025 revenues). Amgen has 17 clinical programs underway in Phase III, eight in Phase II, and 19 in Phase I. Its pipeline includes MariTide, an anti-obesity medication administered once per month by injection. The company receives approximately 80% of its revenues from sales to the three large U.S. drug wholesalers: McKesson Corporation, Cencora, and Cardinal Health. The company is ranked 134th on the Fortune 500 and 202nd on the Forbes Global 2000. In 2020, the company was added to the Dow Jones Industrial Average (DJIA).